Optimal time on HAART for prevention of mother-to-child transmission of HIV.

Objectives: To determine the impact of time between initiating highly active antiretroviral therapy (HAART) and delivery-duration of antenatal HAART-on perinatal HIV infection.

Design: We conducted a retrospective cohort analysis of pregnant HIV-infected women in Lusaka, Zambia. Women in our cohort were receiving HAART and had an infant HIV polymerase chain reaction test between 3 and 12 weeks of life.

Predictors of CD4 eligibility for antiretroviral therapy initiation among HIV-infected pregnant women in Lusaka, Zambia.

Background: In resource-limited settings, CD4 testing is a barrier to antiretroviral therapy initiation in pregnancy.

Methods: We used logistic regression to identify predictors of CD4 cell count ≤ 350 cells/uL in 20,233 pregnant women.

Results: The best-performing model included any 3 of: age ≥ 28 years old, hemoglobin ≤ 9.